Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli

University Hospital Basel

Status: Active, not recruiting

Conditions: Extended Spectrum Beta Lactamases (ESBL) E. Coli

Treatments: Other: examination of blood sample; Other: examination of stool sample; Other: patient questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT04764500

2019-00044 am21Egli;

Details and patient eligibility

About

This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an observational setting exploring natural gastrointestinal decolonization of humans colonized with ESBL E. coli.

Full description

Antibiotic resistance is a severe threat to contemporary medicine. Effective approaches to fight multi-drug resistant pathogenic bacteria are needed.

This clinical observational study is to investigate whether express extended spectrum beta lactamases (ESBL) E. coli colonizing the human gut can be out-competed by other, ideally pan-sensitive strains (non-ESBL E. coli).

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• travelling to Southeast Asia (India, Bhutan, Nepal, Bangladesh, Myanmar, Thailand, Laos, Cambodia, Vietnam) for a maximum of 4 weeks.

Exclusion criteria

• other travelling destinations than mentioned above
• antibiotic use at the first sampling time
• Participants who are not colonized will serve as a control group for microbiome comparison

Trial design

39 participants in 1 patient group

travellers to Southeast Asia

Description:

Clients planning to travel to Southeast Asia will be recruited

Treatment:

Other: patient questionnaire

Other: examination of stool sample

Other: examination of blood sample